True

doi:10.1038/sj/leu/2401501

Cited by 14 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This same study demonstrated that repeated intravenous injections of human TRAIL caused no observable toxicity in non-human primates [19]. Since that time, numerous reports have demonstrated the preferential ability of TRAIL to induce apoptosis in tumor cells, both in vitro and in vivo , while producing minimal toxic side effects in hosts [9,19-21,47-49]. Despite these encouraging results, other reports have shown that many tumor types are resistant to TRAIL (reviewed in [2,4,5]).…”

Section: Overcoming Tumor Cell Resistance To Trail-induced Apoptosismentioning

confidence: 97%

Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer

Norian

James

Griffith

2011

Cancers

View full text Add to dashboard Cite

Numerous biologic approaches are being investigated as anti-cancer therapies in an attempt to induce tumor regression while circumventing the toxic side effects associated with standard chemo- or radiotherapies. Among these, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has shown particular promise in pre-clinical and early clinical trials, due to its preferential ability to induce apoptotic cell death in cancer cells and its minimal toxicity. One limitation of TRAIL use is the fact that many tumor types display an inherent resistance to TRAIL-induced apoptosis. To circumvent this problem, researchers have explored a number of strategies to optimize TRAIL delivery and to improve its efficacy via co-administration with other anti-cancer agents. In this review, we will focus on TRAIL-based gene therapy approaches for the treatment of malignancies. We will discuss the main viral vectors that are being used for TRAIL gene therapy and the strategies that are currently being attempted to improve the efficacy of TRAIL as an anti-cancer therapeutic.

show abstract

Section: Overcoming Tumor Cell Resistance To Trail-induced Apoptosismentioning

confidence: 97%

Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer

Norian

James

Griffith

2011

Cancers

View full text Add to dashboard Cite

show abstract

“…Although earlier reports described TRAILinduced cell death in freshly isolated human multiple myeloma cells [96,97], subsequent studies failed to reproduce this finding in a range of primary leukaemia cells from acute and chronic, myeloid and lymphocytic disease [98][99][100]. More recently TRAIL resistance has been shown in astrocytomas (all four WHO grades), medulloblastomas, meningiomas, esthesioneuroblastoma [3], soft tissue sarcomas [101], glioblastoma cells expressing the mutations of the tumour suppressor gene PTEN (Phosphatase and Tensin homolog deleted on chromosome TEN) [102], and in most breast, lung and colon tumour specimen [103].…”

Section: Trail Monotherapymentioning

confidence: 97%

Is TRAIL the holy grail of cancer therapy?

2009

View full text Add to dashboard Cite

Inducing apoptosis has become an important approach in the development of new anti-cancer treatments. Tumour necrosis factor apoptosis inducing ligand (TRAIL) based therapies have emerged as one of the most promising examples of this as they selectively induce apoptosis in tumour cells. However, many primary tumours are inherently resistant to TRAIL-mediated apoptosis and require additional sensitisation. Here we review apoptotic and non-apoptotic TRAIL-signalling, and the therapeutic effects of TRAIL-based treatments both as monotherapy and in combination with sensitising agents.

show abstract

“…For del(8p) however, it has been shown that this aberration acts as an independently poor prognostic factor for both progression free survival (PFS) and overall survival (OS) [80, 81]. Furthermore, it has been shown that the tumour necrosis factor-related apoptosis-inducing ligand (TRALI) receptor gene is located on 8p, and that during del(8p) a consequential downregulation of TRALI occurs [83]. As TRALI is associated with TNF-induced apoptosis, it is proposed that with reduced receptor expression in del(8p) the sensitivity of tumour cells to TRAIL-medicated apoptosis may be decreased providing an advantage for the immune escape of malignant clones from surveillance by natural killer cells and cytotoxic T lymphocytes [84].…”

Section: Copy Number Variations In Myelomamentioning

confidence: 99%

The Genetic Architecture of Multiple Myeloma

Prideaux

O'Brien

Chevassut

2014

Advances in Hematology

View full text Add to dashboard Cite

Multiple myeloma is a malignant proliferation of monoclonal plasma cells leading to clinical features that include hypercalcaemia, renal dysfunction, anaemia, and bone disease (frequently referred to by the acronym CRAB) which represent evidence of end organ failure. Recent evidence has revealed myeloma to be a highly heterogeneous disease composed of multiple molecularly-defined subtypes each with varying clinicopathological features and disease outcomes. The major division within myeloma is between hyperdiploid and nonhyperdiploid subtypes. In this division, hyperdiploid myeloma is characterised by trisomies of certain odd numbered chromosomes, namely, 3, 5, 7, 9, 11, 15, 19, and 21 whereas nonhyperdiploid myeloma is characterised by translocations of the immunoglobulin heavy chain alleles at chromosome 14q32 with various partner chromosomes, the most important of which being 4, 6, 11, 16, and 20. Hyperdiploid and nonhyperdiploid changes appear to represent early or even initiating mutagenic events that are subsequently followed by secondary aberrations including copy number abnormalities, additional translocations, mutations, and epigenetic modifications which lead to plasma cell immortalisation and disease progression. The following review provides a comprehensive coverage of the genetic and epigenetic events contributing to the initiation and progression of multiple myeloma and where possible these abnormalities have been linked to disease prognosis.

show abstract

True

Cited by 14 publications

References 16 publications

Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer

Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer

Is TRAIL the holy grail of cancer therapy?

The Genetic Architecture of Multiple Myeloma

Contact Info

Product

Resources

About